The relationship between adipose tissue RAAS activity and the risk factors of prediabetes: a systematic review and meta-analysis

References

• Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci. 2013;9(2):191. doi: 10.5114/aoms.2013.33181
   PubMed Web of Science ®Google Scholar
• Moreno-Navarrete JM, Catalán V, Ortega F, et al. Circulating omentin concentration increases after weight loss. Nutr Metab (Lond). 2010;7(1):1–11. doi: 10.1186/1743-7075-7-27
   PubMedGoogle Scholar
• Wurm S, Neumeier M, Weigert J, et al. Plasma levels of leptin, omentin, collagenous repeat-containing sequence of 26-kDa protein (CORS-26) and adiponectin before and after oral glucose uptake in slim adults. Cardiovasc Diabetol. 2007;6(1):1–7. doi: 10.1186/1475-2840-6-7
   PubMedGoogle Scholar
• Zhou J-Y, Chan L, Zhou S-W. Omentin: linking metabolic syndrome and cardiovascular disease. Curr Vasc Pharmacol. 2014;12(1):136–143. doi: 10.2174/1570161112999140217095038
   PubMed Web of Science ®Google Scholar
• Yin L, Huang D, Liu X, et al. Omentin-1 effects on mesenchymal stem cells: proliferation, apoptosis, and angiogenesis in vitro. Stem Cell Res Ther. 2017;8(1):1–14. doi: 10.1186/s13287-017-0676-1
   PubMedGoogle Scholar
• Xu F, Fu-Xing-Zi Li XL, Zhong J-Y, et al. Adipose tissue-derived omentin-1 attenuates arterial calcification via AMPK/Akt signaling pathway. Aging. 2019;11(20):8760. doi: 10.18632/aging.102251
   PubMedGoogle Scholar
• Daneshafrooz A, Yuzbashian E, Zarkesh M, et al. The relation of omentin gene expression and glucose homeostasis of visceral and subcutaneous adipose tissues in non-diabetic adults. Mol Biol Rep. 2022;49(1):163–169. doi: 10.1007/s11033-021-06854-4
   PubMed Web of Science ®Google Scholar
• Greulich S, Chen WJ, Maxhera B, et al. Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies. PLoS One. 2013;8(3):e59697. doi: 10.1371/journal.pone.0059697
   PubMed Web of Science ®Google Scholar
• Yanai H, Yoshida H. Beneficial effects of adiponectin on glucose and lipid metabolism and atherosclerotic progression: mechanisms and perspectives. Int J Mol Sci. 2019;20(5):1190. doi: 10.3390/ijms20051190
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8(11):1288–1295. doi: 10.1038/nm788
   PubMed Web of Science ®Google Scholar
• Wang Y, Li Y, Qiao J, et al. AMPK α1 mediates the protective effect of adiponectin against insulin resistance in INS‐1 pancreatic β cells. Cell Biochem Funct. 2019;37(8):625–632. doi: 10.1002/cbf.3440
   PubMed Web of Science ®Google Scholar
• As A. the association between omentin and diabetes: a systematic review and meta-analysis of observational studies. Diabetes Metab Syndr Obes: Targets Ther. 2019;12:1277. doi: 10.2147/DMSO.S206981
   PubMed Web of Science ®Google Scholar
• Fruhwürth S, Vogel H, Schürmann A, et al. Novel insights into how overnutrition disrupts the hypothalamic actions of leptin. Front Endocrinol. 2018;9:89. doi: 10.3389/fendo.2018.00089
   PubMed Web of Science ®Google Scholar
• Amitani M, Asakawa A, Amitani H, et al. The role of leptin in the control of insulin-glucose axis. Front Neurosci. 2013;7:51. doi: 10.3389/fnins.2013.00051
   PubMed Web of Science ®Google Scholar
• Moonishaa TM, Nanda SK, Shamraj M, et al. Evaluation of leptin as a marker of insulin resistance in type 2 diabetes mellitus. Int J App Basic Med Res. 2017;7(3):176. doi: 10.4103/ijabmr.IJABMR_278_16
   PubMedGoogle Scholar
• Izquierdo AG, Crujeiras AB, Casanueva FF, et al. Leptin, obesity, and leptin resistance: where are we 25 years later? Nutrients. 2019;11(11):2704.
   PubMed Web of Science ®Google Scholar
• Mkhize BC, Mosili P, Ngubane PS, et al. Diet‐induced prediabetes: effects on the activity of the renin–angiotensin–aldosterone system in selected organs. J of Diabetes Invest. 2022;13(5):768–780. doi: 10.1111/jdi.13690
   PubMed Web of Science ®Google Scholar
• Lin X, Xu Y, Pan X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020;10(1):1–11. doi: 10.1038/s41598-020-71908-9
   PubMed Web of Science ®Google Scholar
• Shum M, Pinard S, Guimond M-O, et al. Angiotensin II type 2 receptor promotes adipocyte differentiation and restores adipocyte size in high-fat/high-fructose diet-induced insulin resistance in rats. Am J Physiol Endocrinol Metab. 2013;304(2):E197–E210.
   PubMed Web of Science ®Google Scholar
• López-Jaramillo P, Pradilla LP, Lahera V, et al. A randomized, double blind, cross-over, placebo-controlled clinical trial to assess the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertense subjects with dysglyce mia and abdominal obesity.“ARAMIA”. Trials. 2006;7(1):1–12. doi: 10.1186/1745-6215-7-28
   PubMedGoogle Scholar
• As´ Habi A, Sadeghi M, Arab A, et al. the association between omentin and diabetes: a systematic review and meta-analysis of observational studies. Diabetes Metab Syndr Obes. 2019;Volume 12:1277–1286. doi: 10.2147/DMSO.S206981
   Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):1–11. doi: 10.1186/s13643-021-01626-4
   PubMed Web of Science ®Google Scholar
• Subramanian SK, Caramba SM, Hernandez OL, et al., editors. Is the Downs and black scale a better tool to appraise the quality of the studies using virtual rehabilitation for post-stroke upper limb rehabilitation? 2019 International Conference on Virtual Rehabilitation (ICVR); Tel Aviv University, Tel Aviv, Israel. IEEE; 2019.
   Google Scholar
• Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–384. doi: 10.1136/jech.52.6.377
   PubMed Web of Science ®Google Scholar
• Büttner F, Winters M, Delahunt E, et al. Identifying the ‘incredible’! Part 2: Spot the difference-a rigorous risk of bias assessment can alter the main findings of a systematic review. Br J Sports Med. 2020;54(13):801–808. doi: 10.1136/bjsports-2019-101675
   PubMed Web of Science ®Google Scholar
• von Hippel PT. The heterogeneity statistic I2 can be biased in small meta-analyses. BMC Med Res Methodol. 2015;15(1):1–8. doi: 10.1186/s12874-015-0024-z
   PubMedGoogle Scholar
• Patole S. Forest plots in a meta-analysis. principles and practice of systematic reviews and meta-analysis. Springer; 2021. pp. 79–88. doi: 10.1007/978-3-030-71921-0_8
   Google Scholar
• Alaagib N, Sukkar M, Kardash M. The effects of salt and glucose intake on angiotensin ii and aldosterone in obese and nonobese patients with essential hypertension. Int J Hypertens. 2020;2020:1–9. doi: 10.1155/2020/6017105
   Web of Science ®Google Scholar
• Alphan Z, Berberoglu Z, Gorar S, et al. Increased total renin levels but not angiotensin-converting enzyme activity in obese patients with polycystic ovary syndrome. Med Princ Pract. 2013;22(5):475–479. doi: 10.1159/000351572
   PubMed Web of Science ®Google Scholar
• Barbieri DE, Ribeiro‐Filho FF, Ribeiro AB, et al. Diuretic‐induced potassium depletion and glucose intolerance are not related to hyperactivity of the renin‐angiotensin‐aldosterone system in hypertensive patients with the metabolic syndrome. J Clin Hypertens. 2009;11(10):549–554.
   Web of Science ®Google Scholar
• Dorresteijn JA, Schrover IM, Visseren FL, et al. Differential effects of renin–angiotensin–aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension: a double-blind, placebo-controlled cross-over trial. J Hypertens. 2013;31(2):393–403. doi: 10.1097/HJH.0b013e32835b6c02
   PubMed Web of Science ®Google Scholar
• Engeli S, May M, Nussberger J, et al. Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension. J Am Soci Hypertens. 2017;11(8):488–497. doi: 10.1016/j.jash.2017.06.002
   PubMed Web of Science ®Google Scholar
• Joseph JJ, Echouffo Tcheugui JB, Effoe VS, et al. Renin‐angiotensin‐aldosterone system, glucose metabolism and incident type 2 diabetes mellitus: MESA. J Am Heart Assoc. 2018;7(17):e009890. doi: 10.1161/JAHA.118.009890
   PubMed Web of Science ®Google Scholar
• Srinivasa S, Fitch KV, Wong K, et al. RAAS activation is associated with visceral adiposity and insulin resistance among HIV-infected patients. J Clin Endocrinol Metab. 2015;100(8):2873–2882. doi: 10.1210/jc.2015-1461
   PubMed Web of Science ®Google Scholar
• Brook RD, Bard RL, Kehrer C, et al. Valsartan improves insulin sensitivity without altering vascular function in healthy overweight adults without the metabolic syndrome. Metab Syndr Relat Disord. 2007;5(3):255–261.
   PubMedGoogle Scholar
• Choi GJ, Kim HM, Kang H, et al. Effects of telmisartan on fat distribution: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2016;32(7):1303–1309. doi: 10.1185/03007995.2016.1171204
   PubMed Web of Science ®Google Scholar
• Dadarlat A, Pop D, Procopciuc L, et al. Links between renin-angiotensin system genetic polymorphisms and leptin secretion in obese heart failure patients. Acta Endo (Buc). 2018;14(2):274. doi: 10.4183/aeb.2018.274
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Ferrari I, et al. Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. Hypertens Res. 2011;34(1):145–151. doi: 10.1038/hr.2010.205
   PubMed Web of Science ®Google Scholar
• Moors CC, Blaak EE, van der Zijl NJ, et al. The effects of long-term valsartan treatment on skeletal muscle fatty acid handling in humans with impaired glucose metabolism. J Clin Endocrinol Metab. 2013;98(5):E891–E6. doi: 10.1210/jc.2012-4067
   PubMed Web of Science ®Google Scholar
• Krikken J, Dallinga-Thie G, Navis G, et al. Short term dietary sodium restriction decreases HDL cholesterol, apolipoprotein AI and high molecular weight adiponectin in healthy young men: relationships with renal hemodynamics and RAAS activation. Nutr Metab Cardiovasc Dis. 2012;22(1):35–41. doi: 10.1016/j.numecd.2010.03.010
   PubMed Web of Science ®Google Scholar
• Krum H, McMurray JJ, Horton E, et al. Baseline characteristics of the Nateglinide and Valsartan impaired glucose tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials. Cardiovasc Ther. 2010;28(2):124–132. doi: 10.1111/j.1755-5922.2010.00146.x
   PubMed Web of Science ®Google Scholar
• Malmqvist K, Kahan T, Isaksson H, et al. Regression of left ventricular mass with captopril and metoprolol, and the effects on glucose and lipid metabolism. Blood Press. 2001;10(2):101–110.
   PubMed Web of Science ®Google Scholar
• Morales E, Gutiérrez E, Caro J, et al. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin–angiotensin–aldosterone system among patients with obesity and proteinuria. Nefrología (English Edition). 2015;35(6):554–561.
   PubMed Web of Science ®Google Scholar
• Quesada O, Claggett B, Rodriguez F, et al. Associations of insulin resistance with systolic and diastolic blood pressure: a study from the HCHS/SOL. Hypertension. 2021;78(3):716–725.
   PubMed Web of Science ®Google Scholar
• Han SH, Lee S-J, Oh BC, et al. The additive beneficial effects of ramipril combined with candesartan in hypertensive patients on insulin resistance, plasma adiponectin. Korean Circ J. 2007;37(4):173–179. doi: 10.4070/kcj.2007.37.4.173
   Google Scholar
• van der Zijl NJ, Serné EH, Goossens GH, et al. Valsartan-induced improvement in insulin sensitivity is not paralleled by changes in microvascular function in individuals with impaired glucose metabolism. J Hypertens. 2011;29(10):1955–1962. doi: 10.1097/HJH.0b013e32834a7667
   PubMed Web of Science ®Google Scholar
• La Sala L, Tagliabue E, Vieira E, et al. High plasma renin activity associates with obesity-related diabetes and arterial hypertension, and predicts persistent hypertension after bariatric surgery. Cardiovasc Diabetol. 2021;20(1):1–12. doi: 10.1186/s12933-021-01310-w
   PubMed Web of Science ®Google Scholar
• Min SH, Kong SH, Lee J-E, et al. Association of angiotensin-II levels with albuminuria in subjects with normal glucose metabolism, prediabetes, and type 2 diabetes mellitus. J Diabetes Complications. 2017;31(10):1499–1505.
   PubMed Web of Science ®Google Scholar
• Griffin T, Wall D, Browne G, et al. Associations between glycaemic control and activation of the renin-angiotensin-aldosterone system in participants with type 2 diabetes mellitus and hypertension. Ann Clin Biochem. 2018;55(3):373–384. doi: 10.1177/0004563217728964
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Perico N, Macia M, et al. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int. 2005;68:S57–S65.
   Web of Science ®Google Scholar
• Marcus Y, Shefer G, Stern N. Adipose tissue renin–angiotensin–aldosterone system (RAAS) and progression of insulin resistance. Mol Cell Endocrinol. 2013;378(1–2):1–14.
   PubMed Web of Science ®Google Scholar
• Cooper ME. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens. 2004;17(S2):16S–20S. doi: 10.1016/j.amjhyper.2004.08.004
   PubMedGoogle Scholar
• Underwood PC, Adler GK. The renin angiotensin aldosterone system and insulin resistance in humans. Curr Hypertens Rep. 2013;15(1):59–70. doi: 10.1007/s11906-012-0323-2
   PubMed Web of Science ®Google Scholar
• Thatcher S, Yiannikouris F, Gupte M, et al. The adipose renin–angiotensin system: role in cardiovascular disease. Mol Cell Endocrinol. 2009;302(2):111–117.
   PubMed Web of Science ®Google Scholar
• Liang X, Sun J, Guan H, et al. Angiotensin II inhibits adipogenic differentiation and promotes mature adipocyte browning through the corepressor CtBP1. Biomedicines. 2022;10(12):3131.
   PubMed Web of Science ®Google Scholar
• Kalupahana NS, Moustaid‐Moussa N. The renin‐angiotensin system: a link between obesity, inflammation and insulin resistance. Obesity Rev. 2012;13(2):136–149.
   PubMed Web of Science ®Google Scholar
• Goossens G, McQuaid S, Dennis A, et al. Angiotensin II: a major regulator of subcutaneous adipose tissue blood flow in humans. Journal Of Physiology. 2006;571(2):451–460.
   PubMed Web of Science ®Google Scholar
• Tirosh A, Garg R, Adler GK. Mineralocorticoid receptor antagonists and the metabolic syndrome. Curr Hypertens Rep. 2010;12(4):252–257. doi: 10.1007/s11906-010-0126-2
   PubMed Web of Science ®Google Scholar
• Igbekele AE, Jia G, Hill MA, et al. Mineralocorticoid receptor activation in vascular insulin resistance and dysfunction. Int J Mol Sci. 2022;23(16):8954. doi: 10.3390/ijms23168954
   PubMed Web of Science ®Google Scholar
• Schütten MT, Houben AJ, de Leeuw PW, et al. The link between adipose tissue renin-angiotensin-aldosterone system signaling and obesity-associated hypertension. Physiology. 2017;32(3):197–209. doi: 10.1152/physiol.00037.2016
   PubMed Web of Science ®Google Scholar
• Putnam K, Shoemaker R, Yiannikouris F, et al. The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol. 2012;302(6):H1219–H30. doi: 10.1152/ajpheart.00796.2011
   PubMed Web of Science ®Google Scholar